Myocardial Infarction — Morphological Changes Over Time

• Initial Ischemic Injury (0-20 minutes): Cessation of oxidative phosphorylation leads to depletion of ATP within myocytes. Loss of ATP-dependent ion pump function results in intracellular sodium and calcium accumulation, with reciprocal potassium efflux. Cellular swelling (oncotic necrosis) and mitochondrial calcium overload trigger the opening of the mitochondrial permeability transition pore (mPTP), releasing cytochrome c and activating caspase-mediated apoptotic pathways. During this "ischemic window," myocytes remain viable and morphologically intact under light microscopy, though electron microscopy reveals mitochondrial swelling and relaxation of myofilaments.

• Coagulation Necrosis and Early Reperfusion (20 minutes-12 hours): As ischemia progresses beyond 20 minutes, irreversible myocyte injury becomes manifest as coagulation necrosis—the hallmark pattern in cardiac muscle. Myofilament denaturation occurs, and the loss of striations becomes evident on light microscopy. Hypereosinophilia (increased cytoplasmic pink staining) results from myoglobin release and protein denaturation. If reperfusion occurs during this window, reperfusion injury paradoxically accelerates myocyte death through reactive oxygen species (ROS) generation, calcium-mediated injury, and inflammatory cell infiltration. The wavefront phenomenon describes the progression of necrosis from the subendocardium (most vulnerable due to higher oxygen demand and lower perfusion pressure) toward the epicardium over 6-8 hours in transmural infarction.

• Inflammatory Response (4-72 hours): Early neutrophilic infiltration begins at the border zone by 4 hours, reaching maximal infiltration by 24-72 hours. Neutrophils release proteolytic enzymes, collagenases, and oxygen radicals, further damaging necrotic myocytes and adjacent viable tissue. Contraction band necrosis (alternating hypercontracted and relaxed sarcomeres creating distinctive banding) is pathognomonic for reperfused infarction and appears within hours of reperfusion. By 24 hours, macrophages begin phagocytosis of necrotic debris. The border zone (adjacent to necrotic tissue) shows active hemorrhage, edema, and granulation tissue with prominent capillary proliferation and fibroblasts.

• Atherosclerotic coronary artery disease (85-90% of cases): Rupture of a vulnerable plaque with thin fibrous cap, large lipid core, and abundant macrophages leads to acute thrombosis. ST-elevation myocardial infarction (STEMI) typically results from complete occlusion of a major epicardial coronary artery, most commonly the left anterior descending (LAD; 40-50%), right coronary artery (RCA; 30-40%), or left circumflex (LCx; 15-20%). Non-ST-elevation myocardial infarction (NSTEMI) often reflects incomplete or transient occlusion with some preserved collateral flow.

• Less common causes: Coronary vasospasm (Prinzmetal angina), spontaneous coronary artery dissection (SCAD), coronary embolism, severe anemia, carbon monoxide poisoning, hypoxemia, tachyarrhythmias, severe hypotension, and increased myocardial oxygen demand in setting of fixed stenosis.

• Major risk factors: Hypertension, diabetes mellitus, smoking, hyperlipidemia, obesity, male sex, advanced age, family history of premature CAD, chronic kidney disease, and inflammatory conditions (rheumatoid arthritis, systemic lupus erythematosus).

• Acute chest pain: Sudden onset of severe, substernal chest pain described as "crushing," "pressure," or "heaviness," often radiating to the left arm, neck, jaw, or back. Morphologically correlates with acute myocyte necrosis and inflammatory response activating nociceptors in the myocardial border zone. Typically lasts >30 minutes and is unresponsive to nitroglycerin (unlike angina).

• Autonomic and constitutional symptoms: Diaphoresis (vagal activation and adrenergic response), nausea and vomiting (more common with inferior MI due to vagal stimulation), dyspnea (from acute pulmonary edema if left ventricular dysfunction develops), and a sense of impending doom.

• Physical examination findings: Tachycardia and tachypnea reflecting adrenergic response; pallor and cool extremities from reduced cardiac output; prominent S4 gallop (from reduced ventricular compliance); new murmur of mitral regurgitation (from papillary muscle rupture or ischemic dysfunction); signs of acute heart failure including bilateral crackles, elevated jugular venous pressure, and peripheral edema in large anterior or extensive infarcts affecting left ventricular function.

• Atypical presentations: Elderly patients, those with diabetes, and women may present with dyspnea, fatigue, or vague discomfort without classic chest pain. Dressler syndrome (postinfarction pericarditis) presents 1-8 weeks post-MI with recurrent pleuritic chest pain, pericardial friction rub, and malaise.

• Electrocardiography (ECG): ST-segment elevation ≥1 mm in contiguous leads indicates acute transmural ischemia and warrants emergent reperfusion therapy. T-wave inversion and ST depression reflect subendocardial ischemia or posterior wall involvement. Pathophysiologically, ST elevation results from current of injury between ischemic (negative) and normal (positive) myocardium, visible on ECG during the first 24-48 hours before ST segments normalize.

• Cardiac biomarkers: Cardiac troponins (troponin I and T) are gold standard, detectable within 2-4 hours, peaking at 24-72 hours, and remaining elevated for 7-14 days. Morphologically, troponin release correlates with myocyte membrane disruption during coagulation necrosis. Myoglobin and CK-MB are earlier but less specific markers. Creatine kinase (CK) elevation typically appears 6-12 hours post-MI, peaks at 24-48 hours, and normalizes by 3-4 days. Lactate dehydrogenase (LDH) is slow to rise but remains elevated longest (peaks day 8-10). Presence of serial rise and fall of biomarkers is diagnostic for acute MI.

• Histological findings by temporal stage:
• 0-4 hours (hyperacute stage): No light microscopic changes; electron microscopy shows mitochondrial swelling and relaxation of myofilaments.
• 4-12 hours (acute stage): Coagulation necrosis with loss of striations, wavy myofibers at the border zone, early neutrophilic infiltration, hypereosinophilia, nuclear pyknosis or karyorrhexis.
• 12-24 hours: Dense neutrophilic infiltration, contraction band necrosis (especially prominent in reperfused infarcts), prominent hypereosinophilia, beginning macrophage infiltration, capillary proliferation at margins.
• 1-3 days: Maximal neutrophil infiltration (24-72 hours peak), abundant granulation tissue with fibroblasts, neovascularization, progressive removal of necrotic debris by macrophages.
• 3-10 days: Decreased neutrophil infiltration, prominent macrophage activity, extensive fibroblast proliferation, deposition of early collagen (type III collagen predominates), vascularization and capillary proliferation (appearing as pink granulation tissue).
• 2-8 weeks: Mature scar formation with dense fibrosis, collagen deposition (type I collagen replaces type III), decreased vascularity, and complete resolution of inflammatory infiltrate.
• >8 weeks: Mature fibrous scar (white, avascular tissue), with remaining myofibers showing hypertrophy and disorganization at margins.

• Gross pathology: By 12-24 hours, affected myocardium appears pale and edematous compared to surrounding viable tissue. By 24-48 hours, a hyperemic border zone with dark red hemorrhagic inflammation becomes apparent, creating the classic tan/pale center with dark red border. This color progression reflects transition from necrosis to active inflammation. Transmural infarcts show full-thickness involvement following coronary distribution territories (LAD typically involves anterior wall and anterior septum; RCA involves inferior wall and right ventricle; LCx involves lateral wall). Subendocardial infarcts create a thin band of necrosis in the inner one-third of the left ventricular wall.

• Imaging correlates: Cardiac magnetic resonance imaging (CMR) with late gadolinium enhancement shows infarcted tissue as persistently enhanced regions; best for detecting small infarcts and defining transmural vs. subendocardial extent. Transthoracic echocardiography reveals regional wall motion abnormality (hypokinesis, akinesis, or dyskinesis) in distribution of occluded artery. Coronary angiography (gold standard) identifies culprit lesion and degree of stenosis; allows assessment of TIMI flow grade and thrombus burden.

• Diagnostic criteria: MI is diagnosed by detection of rise and/or fall of cardiac troponin (with at least one value >99th percentile upper reference limit) in conjunction with evidence of myocardial ischemia: symptoms, ECG changes (ST elevation/depression, T-wave changes), imaging evidence of wall motion abnormality, or coronary artery thrombus on angiography.

• Acute phase reperfusion therapy (goal: door-to-balloon time <90 minutes for primary PCI; door-to-needle <30 minutes for fibrinolysis): Primary percutaneous coronary intervention (PCI) with stent placement is preferred revascularization strategy in STEMI, restoring TIMI 3 flow and salvaging myocardium in the ischemic window (most effective if performed within 12 hours but may benefit even later). Rationale: Mechanical reperfusion rapidly restores coronary blood flow, limits infarct size, and reduces mortality. Fibrinolytic therapy (aspirin, clopidogrel, heparin, and thrombolytic agent such as alteplase or tenecteplase) is alternative if PCI unavailable; less effective than PCI but must be given within 12 hours of symptom onset for maximal benefit.

• Antiplatelet and anticoagulation therapy: Aspirin (loading dose 325 mg, then 81 mg daily indefinitely) inhibits platelet aggregation via cyclooxygenase inhibition. P2Y12 inhibitors (clopidogrel, prasugrel, or ticagrelor) given as loading dose followed by maintenance therapy for 12 months (dual antiplatelet therapy). Rationale: Prevent acute stent thrombosis and recurrent events. Unfractionated heparin or enoxaparin provides anticoagulation during acute phase; reduced by newer agents like fondaparinux in stable NSTEMI.

• Beta-blockers: Reduce heart rate, contractility, and blood pressure, decreasing myocardial oxygen demand and limiting infarct expansion. Cardioprotective effects include reduction in reperfusion injury. Contraindicated in acute decompensated heart failure or cardiogenic shock.

• ACE inhibitors or angiotensin II receptor blockers (ARBs): Prevent left ventricular remodeling and reduce afterload. Particularly beneficial in anterior wall MI with reduced ejection fraction or if heart failure develops. Should be started early and continued long-term.

• Statins: High-intensity statin therapy (atorvastatin 80 mg or rosuvastatin 40 mg daily) stabilizes plaques and reduces lipid-driven inflammation. Continued indefinitely regardless of baseline cholesterol.

• Nitrates: Sublingual nitroglycerin for acute anginal symptoms; IV nitroprusside or nicardipine for hypertensive patients or pulmonary edema. Avoid in right ventricular infarction.

• Management of complications: Mechanical circulatory support (intra-aortic balloon pump, extracorporeal membrane oxygenation) for cardiogenic shock unresponsive to inotropes and vasopressors. Urgent surgical repair for acute mitral regurgitation from papillary muscle rupture or ventricular free wall rupture. Implantable cardioverter-defibrillator (ICD) placement if ejection fraction remains ≤35% after 40 days (secondary prevention of sudden cardiac death).

• Monitoring: Serial ECGs, continuous cardiac monitoring for arrhythmias, daily troponin and BNP measurements, transthoracic echocardiography to assess ejection fraction and complications (24-48 hours post-MI and at discharge). Cardiac rehabilitation including exercise training, dietary counseling, and psychosocial support improves outcomes.

• Acute cardiogenic shock (5-10% of STEMI): Occurs when infarcted myocardium exceeds ~40% of left ventricular mass, resulting in loss of contractile function and decreased cardiac output. Mechanism: Extensive myocyte necrosis reduces left ventricular ejection fraction <35%, leading to systemic hypotension (<90 mmHg), tissue hypoperfusion, and end-organ dysfunction. Mortality approaches 50% despite revascularization. Physical findings include hypotension, tachycardia, cool extremities, oliguria, and altered mental status. Requires urgent reperfusion, inotropic support (dopamine, dobutamine), and mechanical circulatory support.

• Acute mitral regurgitation: Results from ischemic dysfunction of papillary muscles (particularly posteromedial papillary muscle supplied by RCA single coronary system) or frank rupture of papillary muscle head. Morphologically, ischemic papillary muscle shows coagulation necrosis without significant inflammation (reflecting acute nature). Acute severe mitral regurgitation causes acute pulmonary edema and cardiogenic shock. Presents with new harsh holosystolic murmur at apex radiating to axilla, acute dyspnea, and hemodynamic collapse. Echocardiography shows prolapsing mitral leaflet with regurgitant jet. Requires urgent mitral valve repair or replacement.

• Ventricular free wall rupture (1-3% of transmural MI, more common in anterior MI): Occurs typically 2-7 days post-MI when necrotic myocardium lacks sufficient fibroblast-mediated support. Morphologically, transmural infarction creates a thinned, friable wall segment vulnerable to rupture during increased ventricular pressure or Valsalva maneuver. Results in sudden hemopericardium and cardiac tamponade with acute cardiovascular collapse, sudden loss of cardiac output, and death within minutes. Classic presentation: sudden severe chest pain followed by shock and loss of pulse. Diagnosis by echocardiography showing pericardial effusion and hemodynamic collapse; confirmed at autopsy/surgery. Emergency surgical repair (pericardial patch) is only chance for survival if recognized, but mortality remains >90% even with immediate intervention.

• Ventricular septal rupture (VSR) (1-2% of transmural MI): Occurs when infarction extends through interventricular septum, typically involving LAD territory (anterior/apical septal rupture) or RCA territory (inferior/basal septal rupture). Usually develops 3-5 days post-MI as necrotic tissue softens. Morphologically, transmural septal infarction leaves a defect allowing left-to-right shunt. Presents with acute dyspnea,

Time-stamp the specimen — the stem gives you a clock

• 0–4 hours: nothing on light microscopy (maybe wavy fibers at the border from tugging by viable neighbors); the answer to "what would you see?" is no change. Death here is from ventricular fibrillation, not pump failure.
• 1–3 days: neutrophils, yellow-pale necrosis, fibrinous pericarditis over a transmural anterior infarct (friction rub, positional pleuritic pain).
• 3–7 days: macrophages clear debris — the wall is at its weakest and this is the peak window for free wall rupture (tamponade), papillary muscle rupture (new holosystolic murmur), and septal rupture (harsh holosystolic murmur at the left sternal border, oxygen saturation step-up from RA to RV on right heart catheterization from a left-to-right LV→RV shunt).
• 1–3 weeks: red-gray granulation tissue, type III collagen, neovascularization.
• >1–2 months: white, avascular type I collagen scar — sets up true aneurysm with mural thrombus and persistent ST elevation weeks after the event.

Buzzwords examiners actually test

• Coagulative necrosis is the pattern after ischemic infarction of the heart and of most solid organs; the brain is the exception (liquefactive), as is any site of bacterial abscess, and granulomatous infection of lung or lymph node gives caseous necrosis. Preserved cell outlines with lost nuclei is the giveaway.
• Contraction band necrosis = successful reperfusion (calcium influx into dying cells), not a separate disease.
• Dressler syndrome weeks later is immune-mediated pericarditis, distinct from early fibrinous pericarditis.

Common distractors to avoid

• Zenker (hyaline) degeneration is necrosis of skeletal muscle — classically rectus abdominis in typhoid fever. It is not a cardiac finding.
• New LBBB alone is not a STEMI criterion: it was removed as a stand-alone criterion in the 2013 ACCF/AHA STEMI guideline; use Sgarbossa/modified Sgarbossa criteria to identify occlusion MI in the setting of LBBB or paced rhythm.
• Troponin stays elevated 7–14 days, so for suspected re-infarction within the first several days, the more useful marker is one that has already normalized — CK-MB.
• ICD for post-MI EF ≤35% waits ~40 days (ACC/AHA/HRS); early implantation does not improve survival because scar maturation and remodeling are incomplete.